Epidermal Langerhans cells in small fiber neuropathies

Subjects with painful small fiber neuropathy, specially in the context of diabetics, had an increased number of the proinflammatory Langerhans cells at the skin. We quantified the immune histiocytic Langerhans cells (LCs) in skin biopsy samples of patients with distal small fiber neuropathy (SFN). P...

Full description

Saved in:
Bibliographic Details
Published inPain (Amsterdam) Vol. 153; no. 5; pp. 982 - 989
Main Authors Casanova-Molla, Jordi, Morales, Merche, Planas-Rigol, Ester, Bosch, Anna, Calvo, Maria, Grau-Junyent, Josep Maria, Valls-Solé, Josep
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Elsevier B.V 01.05.2012
Lippincott Williams & Wilkins, Inc
Elsevier
Subjects
Online AccessGet full text
ISSN0304-3959
1872-6623
1872-6623
DOI10.1016/j.pain.2012.01.021

Cover

More Information
Summary:Subjects with painful small fiber neuropathy, specially in the context of diabetics, had an increased number of the proinflammatory Langerhans cells at the skin. We quantified the immune histiocytic Langerhans cells (LCs) in skin biopsy samples of patients with distal small fiber neuropathy (SFN). Patients were divided according to the presence or absence of neuropathic pain (burning pain) assessed by a visual analogue scale (VAS). We studied 13 diabetic patients (pain-DSFN), 7 nondiabetic patients (pain-SFN) who reported relevant neuropathic pain (VAS ⩾3), and 6 nondiabetic patients without neuropathic pain (no-pain-SFN). Using double immunofluorohistochemistry with the PGP 9.5 and the langerin/CD207, we quantified the intraepidermal nerve fibers density (IENFD) and LCs per square millimeter in the epidermis. A group of 10 skin samples from healthy subjects served as controls. Confocal analysis was performed to evaluate LC PGP 9.5-immunoreactivity. We found a mean value of 334.3LC/mm2 in controls, 310.2LC/mm2 in no-pain-SFN, 329.6LC/mm2 in pain-SFN and 484.3LC/mm2 in pain-DSFN (analysis of variance; P=.01). In patients, analysis of covariance adjusted by different covariables showed that the presence of diabetes (F=5.2, P=.03) was associated with an increased number of LC/mm2. There was a negative correlation between the IENFD and the number of LCs (r2=−0.13, P=.03). No statistically significant differences were found among groups of subjects either for the co-localization or for the number of LCs that were PGP 9.5-immunoreactive (analysis of variance; P>.05). These results indicate that patients with neuropathic pain in the context of SFN, specially those who had diabetes (DSFN), had an increased number of LCs in the epidermis that may play a role in the generation or maintenance of neuropathic pain.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0304-3959
1872-6623
1872-6623
DOI:10.1016/j.pain.2012.01.021